TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
BOTHELL, Wash., Feb. 09, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Leerink Partners 6th Annual Global Healthcare Conference at 1:00 p.m. ET (10:00 a.m. PT) on Thursday, February 16, 2017 in New York, NY. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for 30 days after the live event concludes.
Link: http://wsw.com/webcast/leerink28/aldr
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull or Victoria Meissner Russo Partners, LLC (212) 845-4271 (646) 942-5627 [email protected] [email protected] Investor Relations Contact: David Walsey Alder Biopharmaceuticals (425) 408-8032 [email protected]
